Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 2Phase 3 1Phase 1 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 21Myeloid 3Lymphoid 3Tumor-Agnostic 1Classical hematology 1

Conditions

Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

Epoetin Alfa 27Darbepoetin alfa 13Cytarabine 9Dalteparin 8Rivaroxaban 7Daunorubicin 7apixaban 6Etoposide 6Methotrexate 5Idarubicin 5Heparin, Low-Molecular-Weight 5Cyclophosphamide 5emicizumab 4Tinzaparin 4Thioguanine 4Mitoxantrone 4Granulocyte Colony-Stimulating Factor 4Filgrastim 4Enoxaparin 4pegfilgrastim 3hetrombopag 3epoetin beta 3Saline Solution 3Radiotherapy 3Hydrocortisone 3Erythropoietin 3Dexamethasone 3Aspirin 3Asparaginase 3telapristone acetate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Decitabine × Classical hematology × Clear all
NCT00043134 2010-04-13

Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome

National Cancer Institute (NCI)

Phase 3 Unknown
220 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡